东北制药(000597) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥2,149,397,962.51, representing a 2.57% increase year-over-year[7] - Net profit attributable to shareholders for Q3 2022 was ¥15,547,485.25, a significant increase of 144.57% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached ¥32,044,788.42, up 185.66% year-over-year[7] - The company reported a significant increase in net profit for the first three quarters of 2022, reaching ¥128,138,875.00, which is a 402.55% increase year-over-year[7] - The net profit for the current period is 136,625,529.24, compared to 28,872,569.34 in the previous period, representing a significant increase[29] - The total profit for the current period is 208,566,887.34, up from 55,443,187.51 in the previous period, indicating strong operational performance[29] - The operating profit stands at 227,668,265.75, compared to 78,852,005.54 in the previous period, reflecting improved efficiency[29] - The total comprehensive income for the current period is 140,547,739.77, compared to 28,762,327.09 in the previous period, showing robust growth[32] Earnings and Shareholder Information - The company's basic earnings per share for Q3 2022 was ¥0.0104, an increase of 140.31% compared to the same period last year[7] - Basic earnings per share for the current period is 0.0939, compared to 0.0189 in the previous period, indicating enhanced profitability[32] - The total number of common shareholders at the end of the reporting period was 41,325[16] - The largest shareholder, Jiangxi Fangda Steel, holds 31.12% of shares, totaling 443,231,442 shares[16] - The second largest shareholder, Liaoning Fangda Group, holds 23.10% of shares, totaling 329,068,713 shares[16] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥15,236,406,756.49, reflecting a growth of 15.61% from the end of the previous year[7] - The company's total assets reached ¥15,236,406,756.49, up from ¥13,179,520,955.66, indicating a growth of 15.6%[26] - Total liabilities increased to ¥10,783,462,553.80 from ¥8,889,244,855.46, representing a rise of 21.3%[26] - The total current assets as of September 30, 2022, were approximately CNY 9.04 billion, an increase from CNY 6.80 billion at the beginning of the year[20] - The total non-current liabilities decreased to ¥456,766,569.03 from ¥690,643,300.37, a reduction of 33.8%[26] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥672,684,675.14, which is a 52.81% increase compared to the same period last year[7] - The cash flow from operating activities generated a net amount of 672,684,675.14, an increase from 440,218,469.84 in the previous period[33] - The net cash flow from investing activities is -174,993,183.29, an improvement from -580,488,137.61 in the previous period, indicating better investment management[35] - The net cash flow from financing activities is 677,219,616.16, compared to 454,196,622.11 in the previous period, reflecting effective capital raising efforts[35] Research and Development - Research and development expenses for the period were ¥56,580,000, marking a 66% increase year-over-year due to higher R&D investments[12] - Research and development expenses increased significantly to ¥56,583,004.82, compared to ¥34,009,934.42 in the previous period, marking a growth of 66.6%[27] Strategic Initiatives - The company implemented a restricted stock incentive plan in 2022, incurring equity incentive expenses of ¥39,308,000[7] - The company plans to establish a wholly-owned subsidiary with an investment of CNY 500 million to enhance international collaboration and innovation[19] - The company approved a stock incentive plan with an initial grant of 76.51 million shares at a price of CNY 2.716 per share[19] - The company is in the process of relocating its old factory and has signed a supplementary agreement with local government[19] - The company plans to continue expanding its market presence and investing in new product development[28] Inventory and Receivables - Accounts receivable increased to CNY 2.16 billion from CNY 1.85 billion year-to-date[20] - Inventory as of September 30, 2022, was CNY 1.30 billion, compared to CNY 1.25 billion at the beginning of the year[20]